UCHealth - Cherry Creek

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Bladder cancer4 trials
• Kidney cancer3 trials
• Colorectal cancer2 trials
• Ovarian cancer2 trials
• Prostate cancer2 trials
• Endometrial cancer1 trial
• Lung cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 310 trials
• Phase 23 trials
• Phase 2/33 trials

Status

• Recruiting9 trials
• Active, not recruiting6 trials
• Suspended1 trial

Lead sponsor

• NRG Oncology6 trials
• National Cancer Institute (NCI)5 trials
• Alliance for Clinical Trials in Oncology3 trials
• Canadian Cancer Trials Group1 trial
• ECOG-ACRIN Cancer Research Group1 trial

Running trials

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

  Contact: Tyler Robin (principal investigator)

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  NCT07097142· Phase 3· NRG Oncology· Source

  Contact: Tyler Robin (principal investigator)

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

  Contact: Laura Graham (principal investigator)

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

  Contact: Corbin Eule (principal investigator)

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

  Contact: Virginia F. Borges (principal investigator)

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· NRG Oncology· Source

  Contact: Brian D. Kavanagh (principal investigator)

• Recruiting

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source

  Contact: Marie E. Wood (principal investigator)

• Recruiting

  Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  NCT05327686· Phase 2· NRG Oncology· Source

  Contact: Corbin Eule (principal investigator)

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

  NCT05256225· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

  Contact: Christopher H. Lieu (principal investigator)

• Active, not recruiting

  To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

  NCT04597359· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

  NCT04579224· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Kidney cancer2 recruiting
• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting